Close Menu

NEW YORK – Israeli infectious disease diagnostics firm MeMed is ramping up commercialization efforts for its MeMed BV diagnostic test and its point-of-care MeMed Key testing platform.

The company said this week that the test and platform received CE-IVD marks, allowing it to begin placing them in health centers across the EU. Additionally, MeMed is in the middle of a clinical study in the US that will support a Food and Drug Administration submission and US launch sometime next year.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.